Virax gains on agreement to distribute Marburg virus test kits

Prescient Therapeutics

19/04/2023 13:02

** Shares of biotech company Virax Biolabs  VRAX.O  rise 55%
to 93 cents before the bell
    ** VRAX says it will distribute Marburg virus real-time PCR
testing kits in regions accepting a CE mark
    ** CE marking indicates that a product has been assessed by
the manufacturer and deemed to meet European Union safety,
health and environmental protection requirements
    ** VRAX's test kit is used for the detection of ribonucleic
acid (RNA) from the Marburg virus
    ** Marburg virus disease is a viral haemorrhagic fever that
can have a fatality rate of up to 88%, according to the WHO
    ** As of last close, VRAX was down 17% this year 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))